Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non–muscle-invasive Bladder Cancer

Malmström, 2009, An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer, Eur Urol, 56, 247, 10.1016/j.eururo.2009.04.038 Sylvester, 2002, Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials, J Urol, 168, 1964 Babjuk, 2017, EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016, Eur Urol, 71, 447, 10.1016/j.eururo.2016.05.041 Shariat, 2009, Bladder cancer in the elderly, Urol Oncol, 27, 653, 10.1016/j.urolonc.2009.07.020 Brosch, 2007, Genome plasticity of BCG and impact on vaccine efficacy, Proc Natl Acad Sci U S A, 104, 5596, 10.1073/pnas.0700869104 Leung, 2008, Novel genome polymorphisms in BCG vaccine strains and impact on efficacy, BMC Genomics, 9, 413, 10.1186/1471-2164-9-413 Behr, 2002, BCG--different strains, different vaccines?, Lancet Infect Dis, 2, 86, 10.1016/S1473-3099(02)00182-2 Abufaraj, 2018, What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence, Curr Opin Urol, 28, 570, 10.1097/MOU.0000000000000544 Witjes, 2016, The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer, Urol Oncol, 34, 484.e19, 10.1016/j.urolonc.2016.05.033 Vegt, 1995, A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder, J Urol, 153, 929 Rentsch, 2014, Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy, Eur Urol, 66, 677, 10.1016/j.eururo.2014.02.061 Sengiku, 2013, A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer, J Urol, 190, 50 Kamat, 2013, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers, Eur Urol, 63, 4, 10.1016/j.eururo.2012.09.057 Hall, 2007, Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update, J Urol, 178, 2314 Kamat, 2015, Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer, Nat Rev Urol, 12, 225, 10.1038/nrurol.2015.58 Rink, 2012, Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma, Eur Urol, 61, 854, 10.1016/j.eururo.2011.12.055 Shariat, 2010, Update on intravesical agents for non-muscle-invasive bladder cancer, Immunotherapy, 2, 381, 10.2217/imt.10.1 Karakiewicz, 2006, Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder, BJU Int, 97, 997, 10.1111/j.1464-410X.2006.06036.x Fellows, 1994, Marker tumour response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party), Br J Urol, 73, 639, 10.1111/j.1464-410X.1994.tb07548.x Witjes, 1996, Semin Urol Oncol, 14, 10 Inamoto, 2013, Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: results of a randomized prospective comparison, Urol Ann, 5, 7, 10.4103/0974-7796.106873 Rink, 2013, Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature, Eur Urol, 64, 624, 10.1016/j.eururo.2013.07.007 Oddens, 2013, Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance, Eur Urol, 63, 462, 10.1016/j.eururo.2012.10.039 Lamm, 2000, Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study, J Urol, 163, 1124 Shariat, 2003, Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder, Urology, 61, 1140, 10.1016/S0090-4295(03)00236-X Byrne, 2001, E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup, J Urol, 165, 1473 Abufaraj, 2019, Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes, Eur Urol, 75, 649, 10.1016/j.eururo.2018.11.052 2019, A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens, BJU Int, 123, 11, 10.1111/bju.14417